Good Morning Market Enthusiast,

MAIA Biotechnology (NYSE American: MAIA) just came out swinging.

Market’s open and the company is already moving hard—up big with volume that’s crushing its 3-month average.

This isn’t noise. This is reaction.

MAIA just posted survival results that stunned the field:

17.8 months median overall survival in late-stage NSCLC.

That’s nearly 3X what current treatments offer.

Now under $2 with a $14 price target on the table and a Phase 3 trial on the horizon, the setup looks stronger than ever.

(6)

🧠 Cancer Patients Who Weren’t Supposed to Survive Are Beating the Odds (1)

MAIA’s Phase 2 THIO-101 trial in advanced non-small cell lung cancer (NSCLC) just reported median overall survival of 17.8 months.

That’s triple the 5–6 months typically seen with current standard-of-care chemotherapy. (1)(2) 

And it’s in patients who’ve already failed immune therapy and chemo—arguably the toughest population to treat.

🔁 One Patient. 20+ Months of Stable Disease Before Tumor Shrunk 30% (2)

New data shows a patient in the THIO-101 trial stayed on treatment for 20 months before showing a confirmed partial response (30%+ tumor reduction)—a rare event this late in disease progression.

Even after heavy prior treatments, the safety profile remains solid, and long-term disease control is clearly within reach. (2)

🚨 Zacks Rank #2 = Analysts Bullish (9)

While MAIA recently shifted to a Zacks Rank #2, that still signals strong upside potential based on performance metrics and earnings momentum.

This isn’t speculative chatter—Zacks uses a quantitative model focused on valuation, earnings trends, and institutional interest. 

What’s working:
 

• Technical indicators showing strength (9)
• Clinical milestones delivered on time (1)(2)
• Price momentum aligning with pipeline news
   

📌 $14 Price Target = Room to Run (9)

Updated analyst research still pegs MAIA’s target at $14/share—roughly 400% upside from where it is today.

What’s driving that number?
 

• 17.8 months median OS in THIO-101 (1)
• Phase 3 trial (THIO-104) design approved and set to launch in 2H 2025 (10)
• Orphan designations and FDA fast-track pathways in play (1)(4)
• Strong IP protection and first-in-class mechanism (6)(8)
   

🔬 The Science: How THIO Turns Cancer Inside Out (6)(8)(10)

Ateganosine (THIO) is a first-in-class telomere-targeting dr.ug that selectively kills cancer cells by disrupting their telomeres—a structure they rely on to keep dividing. (6)(8)

But THIO goes further: damaged telomeric fragments trigger cGAS/STING immune signaling, followed by PD-(L)1 checkpoint inhibition. 

The result?
 

• Tumor death
• Immune system activation
• Long-term memory to help prevent relapse (6)
   

This multi-layered mechanism is why THIO is being tested alongside Regeneron’s Libtayo® and now Roche’s Tecentriq®. (3)

(6)

🤝 MAIA + Roche = Validation From the Big Leagues (3)

MAIA recently signed a Master Clinical Supply Agreement with Roche to study THIO in combination with atezolizumab (Tecentriq®) across multiple hard-to-treat cancers.

Roche isn’t a casual collaborator. They’re the #2 oncology player globally—and this deal signals serious faith in MAIA’s mechanism and potential.

🌍 Phase 3 Is Next… and It’s Global (10)

MAIA’s next major step is the launch of the THIO-104 Phase 3 trial—its most pivotal milestone to date. (10)
 

Key features:
 

• Comparing THIO + checkpoint inhibitor vs. chemo in 3rd-line NSCLC
• Global enrollment in Asia, Europe, and the U.S.
• Built for potential FDA submission and commercial alignment (10)
   

🔬 Pipeline Is Expanding Fast (6)(10)
 

MAIA isn’t stopping at NSCLC. It’s building out:
 

• 80+ next-gen THIO compounds
• A Phase 2 trial in hepatocellular carcinoma (HCC), a deadly liver cancer (4)
• Partnerships and collaborations that broaden the addressable market
   

The latest peer-reviewed study confirmed a dual mechanism of action—attacking tumors and bypassing GSTP1-driven dr.ug resistance. 

In plain terms: better efficacy, longer remissions.

🧠 New Advisory Firepower in Liver Cancer (4)

MAIA just added two top-tier HCC experts—Dr. David Pinato and Dr. Claudia Fulgenzi—to its Scientific Advisory Board. Both are global leaders in liver cancer immunotherapy.

Their involvement isn’t just academic—it signals serious intent to go big in liver, where MAIA already holds Orphan Dr.ug Designation.

⚠️ Bottom Line: This Is a Window

Here’s what we know:
 

✅ Zacks Rank #2 = strong b-u-y-side signal (9)
✅ 17.8 months OS = a new clinical benchmark in NSCLC (1)
✅ $14 target = 4x+ current price (9)
✅ Roche partnership = pharma-grade validation (3)
✅ Phase 3 on deck = nearing commercial stage (10)
✅ Liver and pipeline expansion = long-term growth path (4)(6)

 

MAIA is crossing from early-stage promise into late-stage proof.

You don’t have to be told what to do next. You’ve just got to decide if you want to be in before the market finishes recalculating.

Keep your eyes on MAIA (NYSE American: MAIA).

This is where science meets opportunity—and the signal is getting louder.

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://bit.ly/4cLWaog

2. https://bit.ly/4cRuZZk

3. https://bit.ly/42pGNOM

4. https://bit.ly/4cVjJLl

5. https://bit.ly/4jmedDM

6. https://bit.ly/3GjzjEx

7. https://bit.ly/4lIXYlV
8. https://bit.ly/4lKdluq
9.https://bit.ly/430475K
10. https://bit.ly/3GminNn

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 06/30/2025 and ending on 07/01/2025 (the “Campaign”) to publicly disseminate information about MAIA Biotechnology Inc. (MAIA:US). Momentum Media LLC has been compensated $10,000.00 and are owed an additional $0 for the Campaign. To date, we have been paid $52,100.00. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.